A Study of Spiramycin in the Treatment of Patients With AIDS-Related Diarrhea
Single-Blind Efficacy Evaluation of Intravenous Spiramycin in Subjects With AIDS-Related Cryptosporidial Diarrhea
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Listed as NCT00000980, this PHASE1 trial focuses on Cryptosporidiosis and HIV Infections and remains completed. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 5 times since 2026, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Allergy and Infectious Diseases (NIAID)
- Rhone-Poulenc Rorer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Baltimore, United States
- • Cleveland, United States
- • Dallas, United States
- • New York, United States
- • San Diego, United States
- • Worcester, United States